ANO7

Summary

ANO7 (anoctamin 7, HGNC:31677) is a protein-coding gene on chromosome 2q37.3, encoding Anoctamin-7 (Q6IWH7). Has calcium-dependent phospholipid scramblase activity; scrambles phosphatidylserine, phosphatidylcholine and galactosylceramide.

This prostate-specific gene encodes a cytoplasmic protein, as well as a polytopic membrane protein which may serve as a target in prostate cancer diagnosis and immunotherapy. Alternative splicing results in multiple transcript variants encoding different isoforms.

Source: NCBI Gene 50636 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 427 total — 2 pathogenic, 2 likely-pathogenic
• MANE Select transcript: NM_001370694

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31677
Approved symbol	ANO7
Name	anoctamin 7
Location	2q37.3
Locus type	gene with protein product
Status	Approved
Aliases	NGEP, PCANAP5L, IPCA-5
Ensembl gene	ENSG00000146205
Ensembl biotype	protein_coding
OMIM	605096
Entrez	50636

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 8 protein_coding, 5 retained_intron

ENST00000274979, ENST00000402430, ENST00000402530, ENST00000451047, ENST00000459928, ENST00000471606, ENST00000475532, ENST00000481071, ENST00000487192, ENST00000674324, ENST00000880340, ENST00000880341, ENST00000880342

RefSeq mRNA: 2 — MANE Select: NM_001370694 NM_001001666, NM_001370694

CCDS: CCDS33423, CCDS46563

Canonical transcript exons

ENST00000674324 — 25 exons

Exon	Start	End
ENSE00001305115	241218239	241218381
ENSE00001460033	241223662	241223781
ENSE00001460034	241223186	241223276
ENSE00001460036	241217686	241217891
ENSE00001460037	241216093	241216238
ENSE00001460038	241214805	241214902
ENSE00001460039	241212572	241212626
ENSE00001460040	241212094	241212205
ENSE00001460041	241210468	241210570
ENSE00001460042	241210295	241210393
ENSE00001460043	241209498	241209635
ENSE00001460044	241209285	241209428
ENSE00001460045	241207574	241207670
ENSE00001460046	241204865	241204955
ENSE00001460048	241203333	241203498
ENSE00001460049	241202194	241202304
ENSE00001460050	241201298	241201355
ENSE00001460051	241200089	241200225
ENSE00001460052	241199316	241199423
ENSE00001460053	241195703	241195845
ENSE00001460054	241191194	241191251
ENSE00003518153	241223905	241223955
ENSE00003898163	241188677	241188766
ENSE00003898463	241190057	241190171
ENSE00003925683	241224097	241225976

Expression profiles

Bgee: expression breadth ubiquitous, 162 present calls, max score 93.22.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.0344 / max 51.2408, expressed in 1397 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
26504	3.1865	1304
26503	0.3495	174
26505	0.2891	136
26501	0.2049	61
202643	0.0044	1

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ileal mucosa	UBERON:0000331	93.22	silver quality
mucosa of transverse colon	UBERON:0004991	92.76	gold quality
prostate gland	UBERON:0002367	88.65	gold quality
transverse colon	UBERON:0001157	87.58	gold quality
small intestine Peyer’s patch	UBERON:0003454	86.28	gold quality
rectum	UBERON:0001052	85.08	gold quality
small intestine	UBERON:0002108	83.51	gold quality
body of stomach	UBERON:0001161	83.20	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.59	gold quality
mucosa of stomach	UBERON:0001199	79.54	gold quality
stomach	UBERON:0000945	79.14	gold quality
epithelial cell of pancreas	CL:0000083	76.70	gold quality
intestine	UBERON:0000160	76.55	gold quality
colonic epithelium	UBERON:0000397	76.11	gold quality
upper arm skin	UBERON:0004263	75.09	gold quality
colon	UBERON:0001155	74.86	gold quality
kidney epithelium	UBERON:0004819	74.79	gold quality
large intestine	UBERON:0000059	74.68	gold quality
minor salivary gland	UBERON:0001830	73.75	gold quality
fundus of stomach	UBERON:0001160	73.29	gold quality
endothelial cell	CL:0000115	73.24	gold quality
duodenum	UBERON:0002114	72.58	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	72.17	gold quality
mouth mucosa	UBERON:0003729	71.38	gold quality
stromal cell of endometrium	CL:0002255	70.92	gold quality
colonic mucosa	UBERON:0000317	69.91	gold quality
saliva-secreting gland	UBERON:0001044	69.46	gold quality
mucosa of sigmoid colon	UBERON:0004993	69.10	silver quality
C1 segment of cervical spinal cord	UBERON:0006469	68.79	gold quality
spinal cord	UBERON:0002240	67.96	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.96

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

45 targeting ANO7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-548BB-3P	99.86	70.58	4354
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-548AC	99.84	70.77	4351
HSA-MIR-548H-3P	99.84	70.80	4349
HSA-MIR-548Z	99.84	70.80	4349
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-8080	99.82	67.52	1342
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-6752-3P	99.72	66.71	1587
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-1197	99.70	67.75	1027
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-6797-5P	99.61	66.55	2084
HSA-MIR-497-3P	99.61	69.71	1990
HSA-MIR-4261	99.59	70.30	3415

Literature-anchored findings (GeneRIF, showing 12)

• expressed only in prostate and prostate camcer is a promising target for the antibody-based therapies of prostate cancer (PMID:14981236)
• Complete coding sequence of TMEM16G cDNA was determined by assembling 25 exons of TMEM16G gene (PMID:15375614)
• description of the novel prostate-restricted molecule D-TMPP widely expressed in prostate cancer tissues (PMID:15761874)
• NGEP is a glycoprotein with predicted glycosylation sites at N809 and N824. When these residues were converted to glutamine, glycosylation was abolished, confirming that the residues are extracellular (PMID:18676855)
• NGEP is a potential target for T cell-mediated immunotherapy of prostate cancer. (PMID:19495750)
• NGEP protein is widely expressed in low-grade to high-grade prostate adenocarcinomas as well as benign prostate tissues, and the intensity of expression is inversely proportional to the level of malignancy. (PMID:23955683)
• high level of NGEP expression could be associated with good prognosis in prostate cancer (PMID:25808443)
• ANO7 genotypes correlate with expression and biochemical relapse, suggesting that ANO7 is a potential PrCa susceptibility gene and that its elevated expression correlates with disease severity and outcome. (PMID:30157291)
• The interactome of the prostate-specific protein Anoctamin 7. (PMID:32176628)
• Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer. (PMID:33628598)
• The variant rs77559646 associated with aggressive prostate cancer disrupts ANO7 mRNA splicing and protein expression. (PMID:35043958)
• Transcripts of the Prostate Cancer-Associated Gene ANO7 Are Retained in the Nuclei of Prostatic Epithelial Cells. (PMID:36674564)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ano7	ENSDARG00000104834
mus_musculus	Ano7	ENSMUSG00000034107
rattus_norvegicus	Ano7	ENSRNOG00000023427

Paralogs (10): ANO2 (ENSG00000047617), ANO8 (ENSG00000074855), PPP1R7 (ENSG00000115685), ANO1 (ENSG00000131620), ANO3 (ENSG00000134343), ANO4 (ENSG00000151572), ANO10 (ENSG00000160746), ANO5 (ENSG00000171714), ANO6 (ENSG00000177119), ANO9 (ENSG00000185101)

Protein

Protein identifiers

Anoctamin-7 — Q6IWH7 (reviewed: Q6IWH7)

Alternative names: Dresden transmembrane protein of the prostate, IPCA-5, New gene expressed in prostate, Prostate cancer-associated protein 5, Transmembrane protein 16G

All UniProt accessions (5): Q6IWH7, A0A6I8PRE6, A0A6Q8JT31, A0A6Q8JTU6, H7C220

UniProt curated annotations — full annotation on UniProt →

Function. Has calcium-dependent phospholipid scramblase activity; scrambles phosphatidylserine, phosphatidylcholine and galactosylceramide. Does not exhibit calcium-activated chloride channel (CaCC) activity. May play a role in cell-cell interactions.

Subcellular location. Cell membrane. Cell junction. Endoplasmic reticulum Cytoplasm. Cytosol.

Tissue specificity. Specifically expressed in epithelial cells of the prostate (at protein level).

Induction. Up-regulated by androgen.

Miscellaneous. The term ‘anoctamin’ was coined because these channels are anion selective and have eight (OCT) transmembrane segments. There is some dissatisfaction in the field with the Ano nomenclature because it is not certain that all the members of this family are anion channels or have the 8-transmembrane topology.

Similarity. Belongs to the anoctamin family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q6IWH7-1	1, NGEP-L	yes
Q6IWH7-2	2, NGEP-S
Q6IWH7-3	3, D-TMPP

RefSeq proteins (2): NP_001001666, NP_001357623* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007632	Anoctamin	Family
IPR032394	Anoct_dimer	Domain
IPR049452	Anoctamin_TM	Domain

Pfam: PF04547, PF16178

Catalyzed reactions (Rhea), 3 shown:

• a 1,2-diacyl-sn-glycero-3-phosphocholine(in) = a 1,2-diacyl-sn-glycero-3-phosphocholine(out) (RHEA:38571)
• a 1,2-diacyl-sn-glycero-3-phospho-L-serine(in) = a 1,2-diacyl-sn-glycero-3-phospho-L-serine(out) (RHEA:38663)
• a beta-D-galactosyl-(1<->1’)-N-acylsphing-4-enine(out) = a beta-D-galactosyl-(1<->1’)-N-acylsphing-4-enine(in) (RHEA:38899)

UniProt features (30 total): topological domain 9, transmembrane region 8, splice variant 5, region of interest 2, glycosylation site 2, sequence variant 2, chain 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6IWH7-F1	78.56	0.37

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (2): 809, 824

Function

Pathways and Gene Ontology

Reactome pathways

10 pathways

ID	Pathway
R-HSA-2672351	Stimuli-sensing channels
R-HSA-9733458	Induction of Cell-Cell Fusion
R-HSA-1643685	Disease
R-HSA-382551	Transport of small molecules
R-HSA-5663205	Infectious disease
R-HSA-9679506	SARS-CoV Infections
R-HSA-9694516	SARS-CoV-2 Infection
R-HSA-9772573	Late SARS-CoV-2 Infection Events
R-HSA-9824446	Viral Infection Pathways
R-HSA-983712	Ion channel transport

MSigDB gene sets: 65 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_UP, GOBP_PLASMA_MEMBRANE_ORGANIZATION, GOBP_INORGANIC_ANION_TRANSPORT, CHANDRAN_METASTASIS_DN, GOBP_REGULATION_OF_MEMBRANE_LIPID_DISTRIBUTION, GOBP_ORGANOPHOSPHATE_ESTER_TRANSPORT, GOBP_CHLORIDE_TRANSPORT, GOBP_ENDOMEMBRANE_SYSTEM_ORGANIZATION, GOBP_PHOSPHOLIPID_TRANSPORT, GOBP_MEMBRANE_ORGANIZATION, GOBP_LIPID_LOCALIZATION, GOBP_TRANSMEMBRANE_TRANSPORT, GOCC_ANCHORING_JUNCTION, GOMF_LIPID_TRANSPORTER_ACTIVITY, GOMF_PROTEIN_DIMERIZATION_ACTIVITY

GO Biological Process (8): monoatomic ion transmembrane transport (GO:0034220), calcium activated phospholipid scrambling (GO:0061588), chloride transmembrane transport (GO:1902476), lipid transport (GO:0006869), establishment of localization in cell (GO:0051649), calcium activated phosphatidylserine scrambling (GO:0061589), calcium activated phosphatidylcholine scrambling (GO:0061590), calcium activated galactosylceramide scrambling (GO:0061591)

GO Molecular Function (4): intracellularly calcium-gated chloride channel activity (GO:0005229), chloride channel activity (GO:0005254), protein dimerization activity (GO:0046983), phospholipid scramblase activity (GO:0017128)

GO Cellular Component (6): endoplasmic reticulum (GO:0005783), cytosol (GO:0005829), plasma membrane (GO:0005886), anchoring junction (GO:0070161), cytoplasm (GO:0005737), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-8 pathways:

Category	Pathways
Ion channel transport	1
Late SARS-CoV-2 Infection Events	1
Disease	1
Viral Infection Pathways	1
SARS-CoV Infections	1
SARS-CoV-2 Infection	1
Infectious disease	1
Transport of small molecules	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
calcium activated phospholipid scrambling	3
cellular anatomical structure	3
plasma membrane phospholipid scrambling	2
cytoplasm	2
monoatomic ion transport	1
transmembrane transport	1
chloride transport	1
monoatomic anion transmembrane transport	1
transport	1
lipid localization	1
establishment of localization	1
cellular localization	1
chloride channel activity	1
ligand-gated monoatomic anion channel activity	1
intracellularly calcium-gated channel activity	1
monoatomic anion channel activity	1
chloride transmembrane transporter activity	1
protein binding	1
intramembrane lipid carrier activity	1
endomembrane system	1
intracellular membrane-bounded organelle	1
membrane	1
cell periphery	1
cell junction	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

620 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ANO7	ACP3	P15309	772
ANO7	KLK2	P20151	743
ANO7	KLKB1	P03952	686
ANO7	KLK3	P07288	675
ANO7	GBA1	P04062	586
ANO7	RHBDD2	Q6NTF9	506
ANO7	CLCA4	Q14CN2	480
ANO7	CLCA2	Q9UQC9	480
ANO7	MYBPC1	Q00872	475
ANO7	PTPRF	P10586	469
ANO7	KANK1	Q14678	465
ANO7	AR	P10275	463
ANO7	TMEM44	Q2T9K0	462
ANO7	BROX	Q5VW32	459
ANO7	CLCA1	A8K7I4	447

IntAct

0 interactions, top by confidence:

BioGRID (70): ANO7 (Affinity Capture-RNA), ANO7 (Affinity Capture-MS), HSPA1A (Affinity Capture-MS), COPG2 (Affinity Capture-MS), GAR1 (Affinity Capture-MS), NOL10 (Affinity Capture-MS), LLPH (Affinity Capture-MS), HSD17B10 (Affinity Capture-MS), ARPC3 (Affinity Capture-MS), ATP5B (Affinity Capture-MS), COPG1 (Affinity Capture-MS), ALDH18A1 (Affinity Capture-MS), EIF4A1 (Affinity Capture-MS), CAPZB (Affinity Capture-MS), GARS (Affinity Capture-MS)

ESM2 similar proteins: A0A0G2K1Q8, A0A494BA31, B1MTL0, B2RXE2, D3ZBP4, E9Q3M5, F1MH07, O18917, O62667, O88269, P02730, P04919, P04920, P13808, P15575, P16283, P23347, P23348, P23562, P48746, P48751, Q14940, Q14AT5, Q2Y0W8, Q32LP4, Q5DTL9, Q5RB85, Q5RD44, Q60825, Q6IFT6, Q6IWH7, Q6RI88, Q6RVG2, Q6SJP2, Q6U841, Q80ZA5, Q8JZR6, Q8K4V2, Q8NG04, Q8TDZ2

Diamond homologs: A1A5B4, A2AHL1, A6QLE6, P86044, Q14AT5, Q32M45, Q4KMQ2, Q5XXA6, Q6IFT6, Q6IWH7, Q6P9J9, Q75UR0, Q75V66, Q8BHY3, Q8C5H1, Q8CFW1, Q9BYT9, Q9NQ90, Q6PB70, Q9HCE9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

427 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	2
Uncertain significance	264
Likely benign	30
Benign	84

Top pathogenic / likely-pathogenic (4)

Variant ID	HGVS	Classification
153228	GRCh38/hg38 2q37.3(chr2:239507342-241841232)x1	Pathogenic
562613	GRCh37/hg19 2q37.3(chr2:242016876-242783384)x1	Pathogenic
394636	GRCh37/hg19 2q37.3(chr2:242045569-243040217)x1	Likely pathogenic
814382	GRCh37/hg19 2q37.3(chr2:242011633-243199373)x1	Likely pathogenic

SpliceAI

5299 predictions. Top by Δscore:

Variant	Effect	Δscore
2:241190048:T:A	acceptor_gain	1.0000
2:241191183:A:AG	acceptor_gain	1.0000
2:241191183:AT:A	acceptor_gain	1.0000
2:241191184:T:G	acceptor_gain	1.0000
2:241202184:T:G	acceptor_gain	1.0000
2:241202192:A:AG	acceptor_gain	1.0000
2:241202192:AG:A	acceptor_loss	1.0000
2:241202192:AGCT:A	acceptor_gain	1.0000
2:241202193:G:GA	acceptor_gain	1.0000
2:241202193:GC:G	acceptor_gain	1.0000
2:241202193:GCT:G	acceptor_gain	1.0000
2:241202193:GCTG:G	acceptor_gain	1.0000
2:241202193:GCTGT:G	acceptor_gain	1.0000
2:241202272:G:GT	donor_gain	1.0000
2:241202302:G:GT	donor_gain	1.0000
2:241202302:GAC:G	donor_gain	1.0000
2:241202305:G:GG	donor_gain	1.0000
2:241204863:AG:A	acceptor_gain	1.0000
2:241204864:GG:G	acceptor_gain	1.0000
2:241204956:G:GG	donor_gain	1.0000
2:241209429:G:T	donor_loss	1.0000
2:241209430:T:G	donor_loss	1.0000
2:241210289:CCGCA:C	acceptor_loss	1.0000
2:241210290:CGCA:C	acceptor_loss	1.0000
2:241210291:GCAGG:G	acceptor_loss	1.0000
2:241210292:CA:C	acceptor_loss	1.0000
2:241210293:A:AG	acceptor_gain	1.0000
2:241210293:AGGT:A	acceptor_gain	1.0000
2:241210294:G:GG	acceptor_gain	1.0000
2:241210294:GGT:G	acceptor_gain	1.0000

AlphaMissense

5730 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:241217886:A:C	S779R	0.994
2:241217888:C:A	S779R	0.994
2:241217888:C:G	S779R	0.994
2:241209516:T:C	F468L	0.993
2:241209518:T:A	F468L	0.993
2:241209518:T:G	F468L	0.993
2:241201299:T:C	F240L	0.990
2:241201301:C:A	F240L	0.990
2:241201301:C:G	F240L	0.990
2:241203486:T:C	F347L	0.989
2:241203488:C:A	F347L	0.989
2:241203488:C:G	F347L	0.989
2:241212200:G:C	K610N	0.987
2:241212200:G:T	K610N	0.987
2:241202290:T:C	F291L	0.985
2:241202292:C:A	F291L	0.985
2:241202292:C:G	F291L	0.985
2:241217700:T:C	F717L	0.985
2:241217702:C:A	F717L	0.985
2:241217702:C:G	F717L	0.985
2:241218317:T:C	F807L	0.984
2:241218319:C:A	F807L	0.984
2:241218319:C:G	F807L	0.984
2:241203405:T:A	W320R	0.983
2:241203405:T:C	W320R	0.983
2:241217712:T:C	F721L	0.983
2:241217714:C:A	F721L	0.983
2:241217714:C:G	F721L	0.983
2:241217808:C:A	R753S	0.983
2:241200203:T:C	F232L	0.982

dbSNP variants (sampled 300 via entrez): RS1000109921 (2:241221546 T>G), RS1000255005 (2:241215967 T>A,C), RS1000273750 (2:241233637 T>G), RS1000314930 (2:241225806 G>A), RS1000395223 (2:241235668 T>G), RS1000413473 (2:241186727 C>T), RS1000416588 (2:241238089 A>G), RS1000442385 (2:241229817 G>A), RS1000468774 (2:241197375 C>T), RS1000543633 (2:241187515 G>A), RS1000547325 (2:241201707 A>T), RS1000578429 (2:241201850 G>A,T), RS1000622052 (2:241224955 G>A), RS1000631646 (2:241192497 C>A), RS1000674487 (2:241224749 T>C)

Disease associations

OMIM: gene MIM:605096 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST001942_6	Prostate cancer	5.000000e-09
GCST011053_8	Neuroblastoma (pediatric)	7.000000e-14

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases methylation	2
aristolochic acid I	decreases expression	1
sotorasib	affects cotreatment, decreases expression	1
dicrotophos	increases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol A	decreases methylation	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	decreases expression	1
benzo(e)pyrene	decreases methylation	1
abrine	decreases expression	1
trametinib	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
NVP-BKM120	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	affects methylation	1
Cisplatin	decreases expression	1
Methapyrilene	decreases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Tobacco Smoke Pollution	affects expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	decreases methylation, increases methylation	1
Particulate Matter	decreases expression, increases abundance	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_2106	M-07e	Cancer cell line	Female
CVCL_RM07	M-07e/TPO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.